It is not clear why TKI efficacy is worse in CYFRA21‐1‐positive ALK lung cancer, but this will need to be examined in future studies, because many ALK‐positive lung cancers are positive for CYFRA21‐1, as shown in our study. The gene discussed is ALK; the disease is lung carcinoma.